c-car168
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2026 (NCT06935474)
Timeline
2020s
- Jan 1, 2026
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
- Membrane-spanning 4-domains subfamily A member 3Immunity, passive
MS4A3 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06935474 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2026 | AbelZeta, Duke University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbelZeta | For profit | 1 | 1 | 1 | 2026 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2026 |
2 organizations
Page 1 / 1